Shares of this biotech giant have lost 19.2% in the past six months against the industry’s growth of 0.6%. The stock has also underperformed the sector and the S&P 500 Index during this period. BMY ...

LB Pharmaceuticals, which has a schizophrenia medicine headed for late-stage testing, broke one of the longest droughts for ...

COBENFY™ provides a fresh approach to schizophrenia treatment by targeting muscarinic receptors, offering patients a reduction in symptoms of psychosis with fewer metabolic side effects than ...

Detailed price information for Puretech Health Plc ADR (PRTC-Q) from The Globe and Mail including charting and trades.

The high incidence of neurovascular diseases and an aging population are driving robust market growth. Advanced therapeutic ...

Known for producing companies like Karuna Therapeutics, which was sold to Bristol Myers Squibb for $14 billion, and newly launched Seaport Therapeutics, PureTech is now launching a company focused on ...

Karuna Therapeutics, Inc. ((KRTX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...